Log In
BCIQ
Print this Print this
 

LP-261

  Manage Alerts
Collapse Summary General Information
Company Locus Pharmaceuticals Inc.
DescriptionSynthetic oral small molecule tubulin-targeting agent
Molecular Target Tubulin
Mechanism of ActionTubulin inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today